/C O R R E C T I O N -- Veloxis Pharmaceuticals A/S/ Sacramento Bee This subgroup analysis suggests that African Americans experience similar clinical results on LCP-Tacro, once-daily, as with twice-daily tacrolimus and there is evidence to suggest a lower acute rejection rate. We are now looking forward to reviewing ... |
